Michele A Kohli (Michele Kohli)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Systematic Review

Coronavirus Disease

Top Venues

Journal of medical economics

Human vaccines & immunotherapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Kelly Fust, Keya Joshi, Ekkehard Beck, Michael Maschio, Michele A Kohli, Amy Lee, Yuriko Hagiwara, Nicolas Van de Velde, Ataru Igarashi
The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines 12 (4) (2024)
Kelly Fust, Keya Joshi, Ekkehard Beck, Michael Maschio, Michele A Kohli, Amy Lee, Yuriko Hagiwara, Nicolas Van de Velde, Ataru Igarashi
The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines 12 (4) (2024)
Michele A Kohli, Michael Maschio, Shannon Cartier, Joaquin F Mould-Quevedo, Frank-Ulrich Fricke
The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany. Vaccines 10 (9) (2022)
Michael Maschio, Michele A Kohli, Mansoor Ashraf, Michael F Drummond, Milton C Weinstein, Joaquin F Mould-Quevedo
An Economic Comparison of Influenza Vaccines Recommended for Use in Eligible Adults under 65 Years in the United Kingdom. Vaccines 10 (4) (2022)
Michele A Kohli, Michael Maschio, Amy Lee, Kelly Fust, Nicolas Van de Velde, Philip O Buck, Milton C Weinstein
The potential clinical impact of implementing different COVID-19 boosters in fall 2022 in the United States. Journal of medical economics 25 (1) (2022)
Michele A Kohli, Michael Maschio, Joaquin F Mould-Quevedo, Mansoor Ashraf, Michael F Drummond, Milton C Weinstein
The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom. Vaccines 9 (6) (2021)
Michele A Kohli, Michael Maschio, Joaquin F Mould-Quevedo, M Bradley Drummond, Milton C Weinstein
The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom. Human vaccines & immunotherapeutics (2021)